Non-Small Cell Lung Cancer - Metastatic

- IRB#9059: Lung Cancer Mutation Consortium
- IRB#11046: Lung-MAP: Study involving multiple drugs
- IRB# 11851: GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or Atezolizumab In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
- IRB# 11845: GO29431: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) Compared with a Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine for PD-L1-Selected Chemotherapy Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/s0/knight.php